REDWOOD CITY, Calif., July 10, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (Nasdaq: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, announced today certain preliminary unaudited financial and operational results for the three months ended June 30, 2025: Soleno expects its net revenue from the sales of VYKATTM XR, for the three months ended June 30, 2025 to be between $31.0 million and $33.0 million. Soleno has determined net revenue for VY ...

Key Takeaways Assurant partners with Plug to enhance certified pre-owned device offerings and customer experience. The deal boosts Plug's value with Assurant-backed warranties, faster shipping, and better device protection. Assurant gains new revenue streams and improved efficiency through Plug's expanding D2C platform.Assurant, Inc. (AIZ) , a leading global provider of protection solutions for connected devices, vehicles, and homes, has entered a strategic collaboration with Plug, a St. Louis-based direc ...

-- Leading cannabis companies partner to leverage existing IP and brand value in New York -- CHICAGO and MINNEAPOLIS, July 01, 2025 (GLOBE NEWSWIRE) -- Vireo Growth Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), a multi-state, vertically-integrated cannabis operator, is pleased to announce a licensing agreement with Curio Wellness (“Curio”), a cGMP-certified, vertically-integrated cannabis company and market-leading innovator of health and wellness products. This strategic partnership will bring ...

Investor Presentation 1Q25 Report Prepared in accordance with China Accounting Standards Contents 1 Performance Highlights and Financial Review 2 Innovation and Internationalization 3 Pharmaceutical 1Q25 Financial Review (1/2) Revenue RMB 9,420 million (-7.26%YoY) R&D Expense RMB 737 million (-11.10%YoY) Net Operating Cash Flow RMB 1,056 million (+15.08%YoY) 4 Med Tech 5 Healthcare Services 6 Appendix Performance Highlights and Financial Review Net Profit Attributable to Shareholders RMB 765 million (+25.42 ...

Core Viewpoint - AJP Holding Company and Orbic North America, holding approximately 19% of Sonim Technologies, are urging fellow stockholders to support their nominees for the board in light of Sonim's poor financial performance and management practices [1][2][3]. Financial Performance - Sonim reported a net loss of $33.65 million in 2024, equating to a loss of $7.13 per share, and has experienced a stock price decline of 87% in 2024, culminating in a total stock value loss of 98% over the past five years [6][15][16]. - The company has accumulated losses totaling $86.45 million from 2021 to 2024, indicating a pattern of poor financial management [6][15]. Management and Governance Issues - The current board and management have been accused of poor stewardship, engaging in entrenchment efforts, and failing to provide a strategic evaluation process that benefits stockholders [2][6][19]. - Sonim's board has implemented anti-takeover measures, including a poison pill strategy and dilutive stock offerings, which have negatively impacted stockholder value [6][7][19]. Proposed Changes - AJP and Orbic are nominating five independent candidates for the board, emphasizing the need for new leadership with industry expertise to conduct a strategic assessment of Sonim [3][11]. - The nominees are expected to advocate for a strategic review process and engage with Orbic regarding acquisition proposals, which could potentially unlock stockholder value [11][12]. Acquisition Proposals - Orbic has made a cash offer of $25 million to acquire substantially all of Sonim's assets, representing a 66.7% premium over another proposed transaction with Social Mobile [10][12]. - The proposed transaction with Social Mobile is viewed as unlikely to provide meaningful returns to stockholders, with estimates suggesting a per-share value of approximately $1.46, which could decrease further when accounting for transaction costs and existing debt [10][20]. Stockholder Engagement - AJP and Orbic are calling on stockholders to vote for their nominees to ensure a transformation in leadership that prioritizes stockholder interests and addresses the company's financial challenges [8][21][22].

Offer to acquire substantially all of Sonim's assets for a cash purchase price of $25 millionPurchase price equates to a price per share of $2.418Hauppauge, New York--(Newsfile Corp. - June 26, 2025) - Orbic North America, LLC ("Orbic"), an international leader in mobile technology innovation, sent a revised acquisition proposal letter to Sonim Technologies, Inc. (NASDAQ: SONM) ("Sonim" or the "Company"), today in which Orbic re-emphasized Orbic's interest in negotiating a mutually agreeable transaction wi ...

June 18, 2025 02:42 PM GMT China Healthcare | Asia Pacific Weekly Rx Express 2025.06.13 China Healthcare Asia Pacific Industry View Attractive Morgan Stanley does and seeks to do business with companies covered in Morgan Stanley Research. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of Morgan Stanley Research. Investors should consider Morgan Stanley Research as only a single factor in making their investment decision. For analyst cer ...

REDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In Hope: International Prader-Willi Syndrome Conference, which will be held June 24-28, 2025, in Phoenix, AZ. The conference represents a unique collaboration between the Prader-Willi Syndrome Association | USA (PWSA | USA), the Foundatio ...

Conference is the first-ever international meeting jointly hosted by the Prader-Willi Syndrome Association | USA, the Foundation for Prader-Willi Research, and the International Prader-Willi Syndrome OrganisationREDWOOD CITY, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced one oral and six poster presentations at the 2025 United In Hope: International Pra ...

Summary of Celeno Therapeutics Conference Call Company Overview - Celeno Therapeutics is based in Redwood Shores, San Francisco Bay Area, with approximately 140 employees and rapid growth [1] - The company has a single asset, DCCR (Dizoxidicholine Extended Release Tablets), now known as VICAT XR, approved by the FDA for treating hyperphagia in patients with Prader Willi syndrome (PWS) aged four years and older [1][6] Industry Context - Prader Willi syndrome (PWS) is a rare genetic neurobehavioral metabolic disorder occurring in about 1 in 15,000 births [3] - The hallmark symptom of PWS is hyperphagia, characterized by an insatiable desire to eat, leading to severe health risks and caregiver burdens [4][5][6] Clinical Development and Efficacy - VICAT XR is the first treatment approved for hyperphagia in PWS, with a clinical program demonstrating significant reduction in hyperphagia [7] - The clinical trials began in 2018, with the primary endpoint readout in June 2020 showing no statistical significance, attributed to COVID-19 impacts [8][9] - A subsequent randomized withdrawal phase in September 2023 yielded statistically significant results, indicating the drug's effectiveness [9][10] Safety Profile - The safety profile of DCCR is consistent with its parent molecule, diazoxide, with common adverse events including hypertrichosis, edema, and hyperglycemia, typically self-limiting [12] - Only two severe adverse events reported during the clinical program [12] Commercial Opportunity - The estimated market opportunity for VICAT XR in the US is over $2 billion, with approximately 12,000 individuals living with PWS in the US and an addressable market of about 10,000 patients [13][14] - A concentrated group of 300 healthcare providers (HCPs) primarily treats 2,100 PWS patients, providing a focused commercial strategy [15] Launch Strategy - The launch strategy for VICAT XR includes a robust clinical program, a strong commercial team, and deep engagement with payers and the PWS community [15][16] - The company has established a field force team with experience in rare disease launches and is working closely with payers to ensure coverage [16][20] Payer Engagement - Payers are receptive to the value proposition of VICAT XR, recognizing the urgent need for hyperphagia treatment and the drug's efficacy [20] - The company offers SILONO-one for end-to-end patient support, ensuring access to the drug and educational resources [21] European Market Potential - PWS is a global condition, with an estimated 9,500 individuals living with PWS in the EU, presenting a strong opportunity for VICAT XR [23] - The company has submitted a Marketing Authorization Application (MAA) to the EMA, with validation announced in May 2025 [24] Financial Highlights - Celeno Therapeutics reported a strong balance sheet with $290 million in cash at the end of Q1, allowing for the execution of its commercial strategy [2][25] - The company has 55 million shares outstanding and minimal debt [25]